{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:02:40Z","timestamp":1784343760143,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.farma.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T21:03:21Z","timestamp":1771448601000},"page":"T144-T150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain"],"prefix":"10.1016","volume":"50","author":[{"given":"Eduardo","family":"Tejedor-Tejada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gonz\u00e1lez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Puy","family":"Goyache Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Su\u00f1\u00e9-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Serrano-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"S\u00e1nchez-del Hoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2026.01.003_bb0005","author":"World Health Organisation"},{"key":"10.1016\/j.farma.2026.01.003_bb0010","author":"World Health Organisation. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)"},{"issue":"3","key":"10.1016\/j.farma.2026.01.003_bb0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Myoung J., et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.farma.2026.01.003_bb0020","author":"European Medicines Agency. Amsterdam: European Medicines Agency. Kaletra: EPAR \u2013 product information"},{"key":"10.1016\/j.farma.2026.01.003_bb0025","author":"Drug Information Center of the Spanish Agency of Medicines and HealthProducts. (AEMPS - CIMA). Madrid. Dolquine: Drug data sheet. Last review 2023"},{"key":"10.1016\/j.farma.2026.01.003_bb0030","author":"Drug Information Center of the Spanish Agency of Medicines and Health Products. (AEMPS - CIMA). Madrid. Azithromycin: Drug data sheet Last review 2003"},{"key":"10.1016\/j.farma.2026.01.003_bb0035","unstructured":"Real Decreto 1090\/2015, de 4 de diciembre, por el que se regulan los ensayos cl\u00ednicos con medicamentos. Bolet\u00edn Oficial del Estado, n\u00fam. 307, 24 de diciembre de 2015, pp. 121069\u2013121131. [Accessed 10 Feb 2025]. Available from: https:\/\/www.boe.es\/boe\/dias\/2015\/12\/24\/pdfs\/BOE-A-2015-14082.pdf"},{"issue":"6","key":"10.1016\/j.farma.2026.01.003_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO Solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.farma.2026.01.003_bb0045","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2026.01.003_bb0050","author":"Espa\u00f1a, l\u00edder europeo en investigaci\u00f3n cl\u00ednica con medicamentos. Agencia Espa\u00f1ola del Medicamento. Feb 2025"},{"key":"10.1016\/j.farma.2026.01.003_bb0055","unstructured":"Castro-Balado A., Varela-Rey I., Band\u00edn-Vilar E.J., Busto-Iglesias M., Garc\u00eda-Quintanilla L., Mondelo-Garc\u00eda C., et al. Clinical research in hospital pharmacy during the fight against COVID-19. Farm Hosp. 2020;44(7):66\u201370. English. doi:10.7399\/fh.11494."},{"key":"10.1016\/j.farma.2026.01.003_bb0060","author":"IQVIA. Assessing the clinical trial ecosystem in Europe"},{"key":"10.1016\/j.farma.2026.01.003_bb0065","doi-asserted-by":"crossref","first-page":"106709","DOI":"10.1016\/j.cct.2022.106709","article-title":"Neumann S., et al. COVID-19 interventional trials: analysis of data sharing intentions during a time of pandemic","volume":"115","author":"Larson","year":"2022","journal-title":"Contemp Clin Trial"},{"issue":"4","key":"10.1016\/j.farma.2026.01.003_bb0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/ddr.21762","article-title":"Review of registered clinical trials for the treatment of COVID-19","volume":"82","author":"Babaei","year":"2021","journal-title":"Drug Dev Res"},{"issue":"6","key":"10.1016\/j.farma.2026.01.003_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039978","article-title":"Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis","volume":"10","author":"Mehta","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.farma.2026.01.003_bb0080","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41467-021-21220-5","article-title":"Hung A., et al. Methodological quality of COVID-19 clinical research","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.farma.2026.01.003_bb0085","unstructured":"Johns Hopkins University Bloomberg School of Public Health. Majority of first-wave COVID-19 clinical trials have significant design short comings, study finds. Science Daily. [Accessed 20 Feb 2025]. Available from: www.sciencedaily.com\/releases\/2020\/06\/200609130006.htm"},{"key":"10.1016\/j.farma.2026.01.003_bb0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejim.2020.07.002","article-title":"Waste in COVID-19 clinical trials conducted in western Europe","volume":"81","author":"Dal-R\u00e9","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.farma.2026.01.003_bb0095","article-title":"Hydroxychloroquine for COVID19: the curtains close on a comedy of errors","volume":"11","author":"Schwartz","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.farma.2026.01.003_bb0100","doi-asserted-by":"crossref","unstructured":"Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et bal. Retracted: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. Epub 2020 Mar 20. Retraction in: Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016\/j.ijantimicag.2024.107416. doi:10.1016\/j.ijantimicag.2020.105949.","DOI":"10.1016\/j.ijantimicag.2024.107416"},{"issue":"1","key":"10.1016\/j.farma.2026.01.003_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12874-023-02110-4","article-title":"Exploring trial publication and research waste in COVID-19 randomised trials of hydroxychloroquine, corticosteroids, and vitamin D: a meta-epidemiological cohort study","volume":"24","author":"Fincham","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.farma.2026.01.003_bb0110","doi-asserted-by":"crossref","first-page":"1198088","DOI":"10.3389\/fmed.2023.1198088","article-title":"Ory M.G., et al. External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations","volume":"10","author":"Silva","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.farma.2026.01.003_bb0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.20458","article-title":"Fowler R., et al. Barriers, solutions, and opportunities for adapting critical care clinical trials in the COVID-19 pandemic","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.farma.2026.01.003_bb0120","doi-asserted-by":"crossref","unstructured":"Showell M.G., Cole S., Clarke M.J., DeVito N.J., Farquhar C., Jordan V. Time to publication for results of clinical trials. Cochrane Database Syst Rev. 2024 Nov 27;11(11):MR000011. doi:10.1002\/14651858.MR000011.pub3 .","DOI":"10.1002\/14651858.MR000011.pub3"},{"key":"10.1016\/j.farma.2026.01.003_bb0130","author":"Asociaci\u00f3n Espa\u00f1ola contra el C\u00e1ncer. Comprometidos con la investigaci\u00f3n en c\u00e1ncer"},{"issue":"6","key":"10.1016\/j.farma.2026.01.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105427","article-title":"COVID-19 as a source of poor publications","volume":"89","author":"Maisonneuve","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"8","key":"10.1016\/j.farma.2026.01.003_bb0140","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Bell J.L.,et al. Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"6490","key":"10.1016\/j.farma.2026.01.003_bb0145","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.abc1731","article-title":"Against pandemic research exceptionalism","volume":"368","author":"London","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.farma.2026.01.003_bb0150","author":"European Medicines Agency"},{"key":"10.1016\/j.farma.2026.01.003_bb0155","author":"J\u00faarez-Gimenez"},{"key":"10.1016\/j.farma.2026.01.003_bb0160","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:20:04Z","timestamp":1784341204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1130634326000061"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.01.003","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.10.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}